TGTX · Tg Therapeutics, Inc.
$53.48
-1.39 (-2.53%)
At close · Jul 29
Market Cap
$8.19B
Shares
153.08M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$400,000,000
as of 2026-03-31
· total across 2 concurrent programs
Remaining Authorization
$0
as of 2025-12-31
Program Utilization
100.0%
$400,000,000 used of $400,000,000
Concurrent Repurchase Programs
| Authorized | As of | Remaining | Remaining as of | Source |
|---|---|---|---|---|
| $300,000,000 | 2026-03-31 | — | — | 10-Q, filed 2026-05-06 |
| $100,000,000 | 2024-08-02 | — | — | 10-Q, filed 2026-05-06 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2015-12-31 | $0 | 10-K, filed 2016-03-15 |
| 2014-12-31 | $0 | 10-K, filed 2016-03-15 |
| 2014-03-31 | $234,337 | 10-Q, filed 2014-05-14 |
| 2013-12-31 | $149,799 | 10-K, filed 2016-03-15 |
| 2013-09-30 | $84,538 | 10-Q, filed 2013-11-14 |
| 2013-06-30 | $84,538 | 10-Q, filed 2013-08-09 |
| 2013-03-31 | $84,538 | 10-Q, filed 2013-05-14 |
| 2012-12-31 | $84,538 | 10-K, filed 2014-03-07 |
Key facts
CIK
1001316
CUSIP
88322Q108
13F (30d)
116 filings
116 filers
Visit website
Investor relations